Skip to main content
Premium Trial:

Request an Annual Quote

Morpho to Market IntegenX's RapidHit System

NEW YORK (GenomeWeb) – Biometric solutions firm Morpho will market IntegenX's RapidHit DNA analysis system to law enforcement and government agencies in certain countries as part of a deal announced today.

Morpho, part of the Safran group, will offer DNA solutions and support services, it said, adding that IntegenX's technology allows it to "deliver powerful solutions capable of accelerating investigations, particularly during the custody period."

The RapidHit system is an automated platform that generates DNA profiles from reference samples. According to Morpho, it is the first rapid DNA technology to use chemistry approved by the FBI, "enabling the upload of DNA profiles to the National DNA Index System," which contains DNA profiles from federal, state, and local participating forensic laboratories.

Financial and other terms were not disclosed.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.